Cerity Partners LLC Buys Shares of 32,174 Fate Therapeutics, Inc. (NASDAQ:FATE)

Cerity Partners LLC bought a new position in Fate Therapeutics, Inc. (NASDAQ:FATE) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 32,174 shares of the biopharmaceutical company’s stock, valued at approximately $120,000.

Several other hedge funds also recently modified their holdings of FATE. Epiq Partners LLC bought a new stake in Fate Therapeutics in the fourth quarter worth $38,000. Fox Run Management L.L.C. bought a new stake in shares of Fate Therapeutics during the 3rd quarter worth about $25,000. Simplicity Solutions LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter worth about $25,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Fate Therapeutics in the 3rd quarter valued at approximately $30,000. Finally, Nisa Investment Advisors LLC raised its stake in shares of Fate Therapeutics by 1,069.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 16,840 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 15,400 shares in the last quarter. Institutional investors and hedge funds own 97.54% of the company’s stock.

Fate Therapeutics Stock Down 2.2 %

Shares of FATE opened at $3.95 on Wednesday. The stock’s 50-day moving average price is $6.59 and its 200 day moving average price is $4.62. The firm has a market capitalization of $449.59 million, a price-to-earnings ratio of -2.42 and a beta of 1.66. Fate Therapeutics, Inc. has a 12-month low of $1.63 and a 12-month high of $8.83.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. The business had revenue of $1.68 million for the quarter, compared to analysts’ expectations of $0.85 million. Fate Therapeutics had a negative return on equity of 38.17% and a negative net margin of 253.30%. During the same period in the previous year, the business posted ($0.58) earnings per share. Equities research analysts expect that Fate Therapeutics, Inc. will post -1.94 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on FATE shares. Morgan Stanley increased their price target on Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, February 27th. Bank of America lifted their target price on shares of Fate Therapeutics from $2.00 to $6.00 and gave the stock an “underperform” rating in a report on Thursday, March 28th. Oppenheimer restated a “market perform” rating on shares of Fate Therapeutics in a report on Tuesday, February 27th. BMO Capital Markets lifted their price objective on Fate Therapeutics from $6.00 to $7.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 27th. Finally, Wedbush restated a “neutral” rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.73.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.